European Journal of Medical Genetics and Clinical Biology Volume 1, Issue 5 | 2024

JMGCB
ISSN:3032-1085
https://doi.org/10.61796/jmgcb.v1i5.453

Harnessing CRISPR-Cas for Targeted Epigenetic Manipulations: a physiological study of Gene Regulation

Qammar Shaker Hmood
Department of Biology, College of Science, University of Thi-Qar
qammar.shaker@sci.utq.edu.iq

Received: March 22, 2024; Accepted: Apr 29, 2024; Published: May 10, 2024;

Abstract: Genome engineering, epigenome editing, as one of the prominent research techniques, has also become instrumental in discovering the gene expression regulation mechanisms and exploring their physiological correlates in health and pathology. This review summarizes the state-of-the-art CRISPR-Cas strategies that focus on epigenetics modification and projects its utility in molecular physiology of gene regulation. In this course we will delve into how CRISPR-Cas systems interact with epigenetic signals through DNA methylation, histone modifications and accessibility to chromatin. Then we look at the physiological effects of epigenetic modulations in cellular differentiation and development, cellular signal and homeostasis, disease pathogenesis, and therapeutic for application. Issues and perspectives on how epigenome manipulations can revolutionize therapeutics are also emphasized exploring the potential of precision medicine and individualized therapies. Overall, the review stresses the pivotal role of epigenetic modulation in the development of our understanding of gene expressions/mediation and cellular physiology. It also provides some inputs on the potential directions that the field of genetic engineering might take in the future.

Keywords: DNA methylation, Gene Regulation, CRISPR-Cas

Introduction

The arrival of CRISPR-Cas lost no time to be a game-changer in the whole genetic engineering field where it unequivocally brought about unprecedented level accuracy in genetic engineering. Initially, the CRISPR-Cas technology was highly appraised as for the way that it precisely replaced the DNA sequences, but nowadays it is seen to work at a higher level than only inside cells where it starts to focus on epigenetic effects. Epigenetic alterations in gene expression mechanism, but without changes in DNA structure, constitute a system which determines cell identity, development and response to external cues. Comprehending the interaction between epigenetic aberrances and intricate genetic regulations is vital to unveiling the dynamics of bodily functions (Statello et al., 2021).

CRISPR- Cas system as a means to single out the epigenetic audience for exploring the mutual influence between chromatin structure, epigenetic marks, and gene expression has become a top-notch instrument in recent years. Through this strategy, researchers have the ability to control the epigenome of genes precisely at the preselected genomic point, thus bringing new dimensions into the physiological quest of gene regulation. CRISPR-Cas systems with sequence-specificity avoids indirect consequences of editing genome by allowing researchers to examine the functional consequences of epigenetic modifications in a methodical and context-dependant fashion (Muhar et al., 2018).

The next is that this critical review intends to give the best understanding of the modern methods of applying CRISPR-Cas system for the target epigenetic treatments with the recognition to its importance in the gene expression regulation. We would see that the basic principles which underlie CRISPR-based epigenome editing can be understood by looking at the complicated system of mechanisms that are involved in DNA modification, the way that these changes regulate gene expression and the significance of this process to physiological functioning. In the next part, we will summarize the prospective of CRISPR based epigenome editing in revealing the molecular mechanism of complex physiological processes which may comprise of development and differentiation processes up to the disease pathogenesis probing and disease therapeutic interventions (Herrera et al., 2019).

Primarily, the review reinforces the fact that CRISPR-Cas technology is a game changer in the way we go about uncovering the complexities of epigenetic regulation and gene expression. Also, the technology allows us to study these phenomena from a physiological angle. Through equipping researchers with the indispensable tool for the precise manipulation of the epigenome, CRISPR-based epigenome editing is endowed with an enormous potential in answering where the complex regulatory processes operate and what purpose they contracted within a cell. Using an intertwine form of novel research findings and inspiring technological developments, our main goal is to discover the future pathways and the possible consequences of this emerging subject for gene regulation studies in physiology (Salgado et al., 2019).

2. CRISPR-Cas System for Epigenetic Manipulations

2.1. Mechanisms of CRISPR-Cas System

CRISPR-Cas technology, originally found to be an adaptive immune response system in bacteria and archaea, has been cleverly converted into a versatile molecular instrument (such as guided genome editing). Having a CRISPR-Cas system as a primary option is its ability to hit specific DNA sequences by a short RNA molecule, which in turn applies site specific intervention. Despite the fact that bringing about changes to DNA was in the first place considered the primary use of CRISPR-Cas technology, recent developments paved the way for additional implementations that provide an epigenome editing ability, thus helping to control gene expression through targeted manipulation of epigenetic marks (Koonin et al., 2019).

The CRISPR-Cas system comprises two main components: the enzyme Cas nucleotide and a guide RNA (gRNA). The gRNA precisely directs the Cas protein to the site it is meant to interact with, by forming paired bonds with the DNA sequence at the target site. This allows the Cas protein to bind to its target region and mediate DNA modification. Upon contacting the genomic DNA, the Cas protein induces the uncoupling of two strands at the target site, and then the cellular DNA repair machinery is activated. Two primary pathways mediate the repair of CRISPR-Cas-induced DSBs: NHEJ and HDR types of DNA repair direct the non-homologous end joining and homologous directed repair. NHEJ is the main repair pathway for DNA DSBs that results in deletions/insertions at the DSB site which may be either disabling or knockout the respective gene. Unlike HDR which employs a use of a special DNA which is repair template to carry out the DSB, HDR has more specific effect and enabling more precise genome editing by introducing normal base pairs at the target locus (Marraffini et al., 2019).

Even though the original purpose of CRISPR-Cas systems was epigenetics rather than DNA editing, scientists got more creative and began to develop intriguing strategies to apply CRISPR technology for epigenetic ecosystems. Directed epigenome editing employs coupled Cas protein with catalytic activity (dCas) and effector domains that alter an epigenetic markers by DNA methyltransferases (DNMTs), histone methyltransferases (HMTs), histone acetyltransferases (HATs) or histone deacetylases (HDACs). When the fusion of dCas with the effector domains is utilized and the gRNA is then employed for the aim of leading the altered DNA, the gene site which is targeted can be specifically manipulated by the researchers. The strategy contributes to analyzing the cause-and-effect relationship between epigenetic alterations as well as gene expression - this provides the epigenetic impact on the physiological condition studied (Marraffini et al., 2019).

Apart from the cell level targeted editing of the epigenome, the CRISPR–Cas system has evolved installation to further indirectly regulate epigenetic conditions by recruitment of chromatin-modifying enzymes. For example, the dCas protein can be connected with some specific DNA-binding protein domains or RNA molecule that only has the capability of recognizing the desired chromatin modifiers, hence, can only bind with the targeted genomic locus. The strategy allows the scientists to modify dynamically the levels of the accessibility of the chromatin, the histone modifications, and also the pattern of the DNA methylation through the creation of linear structures of the DNA in an exact and reversible way, while enabling the identification of the regulatory role of epigenetic marks in gene expression and cellular physiology (Shivram et al., 2021).

Additionally, the CRISPR-Cas system represents an efficient tool to precisely conduct epigenetic alterations, making it possible to unveil the complex mechanism by which chromatin structure, epigenetic marks, and gene expression are associated with each other. Through tailoring CRISPR-Cas to target epigenetic modifications and uncover their functional roles, investigators can detect how changes of this kind might lead to differential gene expression and consequent effects on health and disorders (Shivram et al., 2021).

2.2. Targeting Epigenetic Modifications with CRISPR-Cas

CRISPR-Cas has opened a new door to the exploration of the new unknown regulatory mechanisms which are responsible for the genetic expression and the cellular function at the chromatin level. Lately, numerous scientists have developed some clever engineering and design strategies to guide the CRISPR-Cas-directed epigenome editing, and to set the correct chromatin modifications such as DNA methylation, histone modifications, and chromatin accessibility, as Zhang et al. calls it, and also Chitkara et al. (2022).

2.2.1. DNA Methylation Editing: DNA methylation

Which consists of the marking certain cytosine residues in the dinucleotides of CpG with methyl groups, is the most important factor of gene regulation and cellular identity. Aberrentrations of DNA methylation patterns are identified as factors that play a role in diseases including cancer, neurological problems, as well as those of development. With CRISPR-Cas-based DNA methylation editing we can zone in on DNA methylation patterns at the level of specific genomic loci and approach the contribution of inherited methylation changes to various health conditions through functional studies of altered methylation states (Mahmoud et al., 2019).

One method for epigenetic editing implements a fusion between a provider of the catalytically inactive Cas protein (dCas) and DNMTs, an enzyme that adds methyl groups to DNA. With the help of guide RNA's address, cCas-DNMT fusion proteins will be lacking to specific genomic positions, hence induce DNA methylation changes at target region. However, in dCas2 and TET (Ten-Eleven Translocation) enzyme fusion, the latter would be like mC to eventually lose the methylation mark (Luo et al., 2018).

2.2. 2. Histone Modification Editing:

How modifications in histone chains, methylation, acetylation, phosphorylation and ubiquitylation have come to be defined as additional players in the process of chromatin architecture and gene transcription is a topic of recent interest. One of the most powerful and promising techniques of protein-mediated histone mark editing with CRISPR-Cas system is that it offers researchers the highest precision in modifying specific histone marks at desired genomic loci. The result is that researchers can finally explore the manner and physiological effects of a specific mark (Sankar et al., 2022).

Researchers can also make crossover of dCas with HMT or HAT enzyme (histone methyltransferase enzyme or histone acetyltransferase enzyme) which can bring methylation of the target gene site in a site-dependent manner or acetylation of the target gene site in site-dependent way. Another way in which chromatin can be remodeled is through the relative binding of these agents into the same complex, where HDAC or HDM catalyze removal of acetyl and methyl groups, respectively, leading to the loosening of the end-turn of the helix (Zhang et al., 2021).

2.2.3. Chromatin Accessibility Editing:

That is, these processes occur with two ways; i.e., the nucleosome positioning based on the cytosine methylation. Due to that, the accessibility of the transcription factors and regulatory proteins becomes possible. The development of the CRISPR–Cas9 technique of chromatin accessibility editing has permitted scientists to carry out nucleosome remodeling and DNA inaccessibility control at specific genomic loci that can explain the links between gene expression and regulatory mechanisms (as stated by Liu et al. 2019).

Another way of chromatin accessibility editing can be achieved by fusing dCas protein to a nucleosome remodelling complex or DNA-binding proteins that together bring great changes in the histone positioning. Such fusion proteins can be delivered through the guide RNAs the right tracking sites using them to modify the chromatin structure, such that it becomes more accessible, and as a result, gene expression control can be implemented (Verkuijl et al. , 2019).

Ultimately, CRISPR-Cas systems-based epigenome editing has a potential for disclosing the functional mechanisms of the epigenetic modification that conducts the gene expression control and cellular mechanisms. Such dramatic change in technology pinpoints limitless options for human exploration, as there can be a genome-editing at the molecular level to regulate DNA methylation, histone modification and chromatin activity, or a functional-relevance research in epigenetics for human health and ailments (Xiaoyi et al. , 2023).

3. Physiological Implications of Gene Regulation

Gene operation, involved in subtle yet powerful transcriptional (DNA), post-transcriptional (mRNA), and epigenetic (genetic material) mechanisms, comprise the basis of the functional cellular activities. Accurate manipulation of gene expression is indispensable to preserve cellular homeostasis, control development processes, and provide prompt responses to cellular and environmental sensory systems. Gene deregulation often cause cellular dysfunction and incur a lot of diseases on the body, showing how important it is to study the phenotypical effects of gene regulation (Feliciello et al., 2021).

During the development, Vast signalling and small molecules gene regulatory network observe the specification and differentiation of mixed cell types from pluripotent progenitors. Transcription factors, epigenetic compounds and signaling pathways altogether dictate gene expression patterns, which then push for the determination of the tissue as well as for the morphogenesis of the tissue. The CRISPR-Cas Middleman Epigenome Editor has unexplored power to figure out the pattern of designer mechanism in the development process. The investigators can reveal the causal connections between epigenetic alterations and cell fate determination by using the cutting edge techniques on how genome works at the key loci. They can this way gain the knowledge about epigenetic modifications crucial for processes as development and differentiation (Zhang et al., 2021).

To elucidate this phenomenon, the physiological homeostasis and ability to adapt effectively to environmental adversities are maintained with cells exhibiting dynamic changes in their gene expression profiles in response to internal and external cues. For instance, the ones that are defined through gene shadowing, as well as the cis-trans and in trans-positioning, influence transcriptional and epigenetic mechanisms in the pathways, which are induced by hormones, growth factors, and cytokines. This irregularity can result in the disturbance of cellular homeostasis and could be one reason behind a wide range of pathological conditions like metabolic abnormalities, immune system imady and malignant cancers. By means of the Cas-CRISPR mechanism, scientists select and modify the most vital messengers among the entire signaling machinery, and they do that to find out about the physiological role and disease association of them (Zhang et al., 2021).

Inconsistent and distorted human genes links the beginning of most human diseases like cancer, neurological disorders, cardiovascular diseases and autoimmunity. Proper sensitization of health workers, improved supply of drugs, histone modification processes, chromatin reorganization, and lastly, this group of categories will play a much bigger role in the prevention of communicable diseases. The ability to apply not only the meantioned two CRISPR-Cas systems for editing of the epigenome but also its further dimension for the research of molecular mechanism of determining pathogenesis and discovery of new possible drug targets of complex diseases makes the scientists more confident about their efforts. Similarly, the epigenetic signatures can be corrected by simply removing the aberrant marks or by directing the normal patterns of gene expression; consequently, the cellular functions are recovered and thus the symptoms of the diseases are alleviated (Witzigmann et al., 2020).

With the help of mechanisms of environmental stimulus, there is an intriguing ability of the cells to alter their gene expressions profiles depending on the current situation and thus they can adapt to changing environment. These adaptive responses are a typically a way of genetic regulation through epigenetic modifications which is almost of essential value for a none DNA changer. CRISPR-Cas technology is the approach that Lay the Foundation for epigenome modification which provides a chance that interferes with the method that monitors environmental changes and allows convenient adaptations. What scientists actually do by making the gene modification is that, they are aimed at the modification of epigenetic marks in a specific manner at a specific genome area. They can reveal how the environmental cues turn on and off certain genes resulting in the proper gene expression pattern and functional cells, producing implications on adaptation and resilience (Liang et. al., 2019).

Furthermore, the word gene is the smallest unit of heredity that conveys information from parents to their offspring. However, the contribution of this information does not directly express, rather it requires a certain mechanism to be activated (regulated). The new gateway for investigation of the gene expression by means of CRISPR-Cas and its contribution to health and disease physiology belongs to the area of a great biomedical breakthrough. Through such a technology, researchers will be able to examine the gene regulation networks in detail, discover new therapeutic targets and explore the possibility of personalized treatment regimens. The Voyager's exhibition's primary purpose is to impart the crucial information and revelations gained from one of the most iconic space missions. Recounting the triumphs, obstacles, and lasting contributions of the Voyager program, this exhibition

3.1. Role of Epigenetics in Gene Expression

Underneath epigenetics, the science that studies the heritable changes in gene expression which do not involve alterations in the DNA sequence, there is a fundamental mechanism of how cellular physiology establish and coordinate multiple complex biological processes. Unlike genetic mutations that involve sequence alterations on the central part of DNA (nucleotides), epigenetic modifications allow transcriptional machinery to bind DNA tightly or loosely thereby increasing or decreasing gene expression (Unnikrishnan et al., 2019).

One of the main events that are important in epigenetics that modifies chromatin structure to decide how the genes express is through modification. Chromatin, the unusual genetic material of eukaryotes, is a complex of DNA and proteins that exists in several states, among which one is more open to transcription factors and RNA polymerase enzyme. Histone proteins, in which the DNA is wrapped into nucleosomes, can be subjected to numerous post-translational modifications, such as, acetylation, methylation, phosphorylation, and ubiquitination. The changing sites of histone might lead to different levels of compaction of chromatin structure thereby bringing into it different kind of effector proteins which can both promote or suppress gene transcription (Topper et al., 2020).

For instance, histone acetylation has a transcriptional activating effect as the acetyl groups neutralize the positive charge of histone tails thereby causing a loose association between histone proteins and DNA which then enable the transcriptional complexes to easily access a gene's promoter region. On the flip side, states of histone methylation either bring about activation or repression of gene transcription is a matter of the precise sites and extent of methylation. On the other hand, the same modifications such as trimethylation of H3K4me3 (histone H3 lysine 4 methylated at lysine 4) is often linked with active promoters, but on the other hand, trimethylation of H3K27me3 (histone H3 lysine 27 methylated at lysine 27) (Unnikrishnan et al., 2019).

As well as histone modifications, methylation of DNA features as a second important epigenetic system that is involved in regulating gene expression. CpG islands, which lie usually around promoters or regulatory regions, are the main sites of cytosine methylation at the 5' position, which is more covalent and happens via addition of a methyl group. The DNA methylation patterns are modulated in a dynamic way through the development and differentiation and they are crucial to the process of stable epigenetic information, necessary for cell-specific expression. Mostly, CpG island hypermethylation in gene promoters proceeds by the transcriptional repression methyl groups being recruited by methyl-binding proteins and chromatin modifying complexes which are responsible for chromatin compaction and transcriptional silencing (Lee et al ., 2019).

Furthermore, epigenetic studies appear to be evolving due to novel data that support a role for microRNAs, long non-coding RNAs, and enhancer RNAs, which indirectly regulate gene expression by affecting chromatine structure. These non-coding RNA regulators act in multiple ways like tools, platforms or decoys to synapse chromatin-modifying complexes or transcriptional regulators to particular genetic loci, thus, playing a role in determining genes expression through a contextual and context-sensitive manner (Topper et al., 2020).

In summary, epigenetics can be seen as a smart layer of complexity that integrates the environmental input and mobile signals to change the gene expression patterns and the cellular phenotypes. It is via the epigenetic process of changing the chromatin structure and molecular mechanisms of DNA methylation and non-protein-coded RNA which cellular identity, growth, and responses to environmental stimuli are encoded. Epienectic processes may be disrupted by dysregulation and can result therein to the gene expression programs being affected and many diseases. Of course, this exemplifies the role of physiological epigenetic studies in communicating the importance of understanding the mechanisms of epigenetic regulation (Liang et al., 2019).

3.2. Impact of Epigenetic Manipulations on Cellular Physiology

CRISPR-Cas-mediated epigenome editing opens up the ways to investigate transcriptional regulation in cellular physiology like never before due to that fact that epigenetic engineering, in general, enables the researchers to find out how the cell functions are impacted by epigenetic changes and distinguish between alterations that prevent development and those that are beneficial. With its functions of fine-grained chromatin structure modification, DNA methylation pattern adjustment and histone changes at specific loci, researchers succeed in extracting necessary gene expression regulatory mechanisms and physiological meaning by this sophisticated technique (Nemec et al., 2021).

Cellular Differentiation and Development: Epigenetic modifications stand out as a primary modulators of cellular differentiation and development since they function in the identification and maintenance of uniform gene expression manifold. Epigenome engineering using epigenetic marks modification like DNA methylation and histone modification leads to altering the transcriptional grounds and determine the cell-fation consequences. Cell-type specific gene expression can be controlled by DNA demethylation at the promoter sites of differentiated state-dependent genes, thereby making it possible to reverse cell differentiation and consequently produce induced pluripotent stem cells (iPSCs) from somatic cells. On the other hand, abnormal epigenetic markings types like DNA methylation patterns have the propensity to interfere with growth process hence reproductive diseases and newborn congenital illnesses (Fonseca et al., 2020).

Cellular Reprogramming and Plasticity: Genetic editing through epigenetic manipulations can induce repatterning of the genetic expression to remaining cells and dictate phenotype plasticity. An example is that selective histone modifications or chromatin remodeling can bring about changes in cell form and character and so provide the means through which one cell type can be converted into another, notably without modifying the underlying DNA sequences. At the basis of this cellular reprogramming is also an opportunity for new regenerative medicine applications and disease modeling approaches, so that patient-specific cell types could be obtained for transplantation purposes and/or drug(s) testing ease (da Silva et al., 2019).

Cellular Signaling and Homeostasis: Epigenetic modifications are mediators engaging environmental clues and cellular cues that regulate gene expression and preserves physiological equilibrium. Manipulation of epigenetic mechanisms can interfere with cell signaling and may influence the onset of a disease. Researchers can unveil molecular mechanisms regulating the signaling components through the epigenetic marks modification, which can eventually explain the cellular functionality and disease progression process. For instance, modification of histone acetylation level or DNA methylation at gene promoters can result in down regulation of transcription and thus influence the way of cells' responding to extracellular stimuli, such as, toxin, hostile environment (Chen et al., 2019).

Disease Pathogenesis and Therapeutic Interventions: The epigenetic disturbance associated to a wide variety of human diseases, including cancer, dementia, cardiovascular problems, and autoimmune conditions, is explained. Surgical modification of epigenetic markers might be decisive in reversing abnormal epigenetic marks and epigenetic markers activating genes normally, the process can not differ. Researchers can conduct modifications selectively that are specifically related to the diseases via epigenetic changes associated with the genes that cause diseases and consequently can reverse disease phenotypes and ameliorate patients. Besides that, epigenome- target therapies may well become part of precision medicine schemes that enable one to design specific therapies matching individual patients' epigenetic profiles (Hamilton et al., 2018).

In short, epigenetic reshaping allows us to understand on a molecular level how gene control works and how complex cellular processes happen. Through comprehending the difference between gene expressions and health outcomes because of epigenetics changes, researchers may thereby discover new receptacles of therapy and create entirely new ways of addressing diseases and prevention. Moreover, the skill of accurating and regulating epigenetic marks in a very precise and specific manner may completely revolutionize regenerative medicine, cell reprogramming, and personalized medicine in the near future (Zhang et al., 2018).

3.3. Potential Therapeutic Applications

The elusive relationship between epigenetics and functional biology, has significant implications for the creation of therapeutic medicines aimed at diverse groups of ailments affecting human beings. Epigenomical corrections that can be provoked using CRISPR-Cas technology or other gene modifying methods provide a hope for alleviation of ectopic epigenetic marks, normalization of the gene expression patterns, and recovery of cellular's homeostasis. There is a broad spectrum of the diseases in which epigenetic interventions can be considered applicable, including neuroscience, cancer research, cardiology, and regenerative medicine (Ferrari et al., 2019).

Cancer Therapy: The epigenetic alterations are recognized to be one of the cancer features, and besides facilitating tumor initiation, progress, and metastasis. Aside from the targeted epigenetic therapies, these approaches aim to correct uncontrolled gene expression patterns as in epigenetic modifications that distinguish oncogenes and tumor suppressor genes malfunction. CRISPR-Cas9 epigenome editing technology with signal genes are quite promising since it can be designed to turn on genes of cancer genome drivers or reactivate the epigenetic silencing of the tumor suppressor genes. Otherwise, epigenome-targeted treatments can complement with chemotherapy and immunotherapy, ensuring the enhanced effect and failure of the drugs to evade disease (Xiong et al., 2023).

Neurological Disorders: Epigenetic disorders, for instance, those of neurodegenerative diseases Herpes: Alzheimer's disease, Parkinson's disease, and psychiatric disorders, are pleiad. Through targeting epigenetic regulation, promoter binding, and shaping chromatin structure, it is possible to finely modulate the expression of affected genes in the affected brain regions and to restore neuronal function. Genome editing is aimed at removing or correcting defects in the epigenetic marks of genes associated with diseases. It is an approach to mitigate the adverse neurodegeneration processes and relieve the symptoms, thus slow down the disease progression. With CRISPR-Cas-mediated epigenomics editing, one can make a very precise intention to change or shut off the expression of a gene within the central nervous system, showing a new way for designing particular therapy medicine for diseases of the brain (Choupani et al., 2018).

Cardiovascular Diseases: It is through epigenetic modifications that cardiovascular diseases happen upon a person, one example being heart failure, myocardial infarction and arrhythmias. Precise epigenetic manipulations offer new opportunities to affect cardiac cell gene expression and to regulate the function of most important signaling pathways that can steer cardiac remodeling and malfunction process. The intricate weave of healthy epigenetic marks is corrected by disease progression and researchers aim to return them to normal functioning that prevents bad outcomes. CRISPR-Cas mediated epigenome editing as a means offers a strategy valid for precision therapies pertaining to the cardiovascular diseases by modifying the expression of genes targeted in cardiac tissues (Iranifar et al., 2019).

Regenerative Medicine: Defect is remits service cell regenerative medicine transplantation and tissue engineering could be means through the application epigenetic knowledge. Precise epigenetic alteration can trigger remarkable cellular reprogramming and multifarious pluripotent stem cells' differentiation towards desired cells. The CRISPR-Cas system gives them the possibility to change gene expression at pre-established levels, at the level of the cellular identity and phenotype with high specificity. To achieve this goal, they will experiment with tuning epigenetic signals of lineage specific genes, which will enable them to develop functional cells for future use in cellular therapies and regenerative medicine (Fathollahi et al., 2019).

In sum, the epigenetic treatment is considered as a potent tool which works on various fields of medicine. Through specific intervention against epigenetic modifications that favour disease progression the researchers intend to sum novel therapies that reverse abnormal expression patterns, hamper disease progression, and enhance patient outcome. CRISPR-Cas mediated epigenome editing, the specified tool of epigenetics drugs, could admit to advancing epigenetics therapy with the exact and select target modulation of gene transcription of many diseases (Iranifar et al., 2019).

4. Challenges and Future Directions

However, the vastly profound benefits of epigenetics in terms of understanding cellular physiology and designing therapy is not without several hurdles that more or less need to be tackled in order to completely use the technology to the maximum. Moreover, these scientific initiatives hold the keys for the overall progress and the constant development of epigenetics as a research area (Kular et al., 2018).

Specificity and Off-Target Effects: There are two issues with CRISPR-Cas epigenome editing, namely zeroing in on specific targets and control of off-target impacts. Despite the outstanding precision of the CRISPR-Cas systems, unintentional changes in gene expression can happen (known as off-target editing events) and in the worst case scenario, it can have adverse effects. The superiority of CRISPR-Cas systems over other epigenetic editing tools is enabled by enhancing the specificity of guide RNAs, optimizing the performance of Cas proteins, and developing novel delivery methods which ultimately bring about fewer side effects and higher safety of this approach (Verhoeven et al., 2019).

Delivery and Efficiency: The challenge of the very complicated, precise, and targeted delivery of all CRISPR-Cas components to the desired cells and tissues still remains the main obstacle for epigenetic modifications. Implementing strong and directed epigenetic editing molecules with in vivo delivery standing as a major issue for therapeutic purposes represents one of the key challenges of this technology. Various methods for disrupting delivery efficiency, e.g., viral vectors, nanoparticles and cell-penetrating peptides, are under research pursuit to overcome epigenetic editing efficiency challenges in vivo (Dittami et al., 2021).

Epigenetic Complexity and Plasticity: While the complexity and plasticity of epigenome helps in comprehending the functional effects of epigenetic modifications and their implication for cellular physiology, it creates certain level of challenge at the same time. As a result, the epigenetics' epi-scape, being under the impact of environmental factors, developmental cues, and cellular signaling pathways, leads to even further epigenetic studies' complexity. Unraveling the individual importance of distinct epigenetic changes alongside interplay with their genetic and environmental components is charactered by the use of data integration, complex computer platforms, and sophisticated molecular models (Rong et al., 2022).

Ethical and Regulatory Considerations: As symbolizes the case with the rest of novel biotechnology, ethical and juridical concerns should be precisely articulated to make certain that epigenetic manipulation methods are applied responsibly and equitably. Doubts about the capabilities of epigenetic modification for general upgrading, undesired consequences of germline edition and the equity of treatment access are outstanding issues calling for ethical management, open governance and the participation of society in creating a vision of the use of epigenetics research and technology (Bishop et al., 2019).

Future Directions:

Multiplex Epigenome Editing: With progression in CRISPR-Cas technology, multiplex epigenome editing approaches that can work on manipulation of diverse epigenetic marks at individual genetic places at the same time are being developed. Multiplex editing projection has advantages in discerning intricate regulatory networks, elucidation of cumulative impacts of epigenetic modifications, and development of exact base modulation for therapeutic upscaling (Verhoeven et al., 2019).

Single-Cell Epigenomics: Discoveries in single cell epigenomics suggest the individualised nature of cell variation and regulatory processes at the molecular level. Combining CRISPR-Cas-directive epigenome editing and single-cell epigenetic profiling has remarkable potential to indicate individual cell type-specific landscapes, explain the mechanisms of cell diversity, and help in creating individual specific treatment strategies (Rong et al., 2022).

Epigenome Editing in Disease Models: Extending the epigenome editing technology to disease models of various types through genetic manipulations opens the gateway of discovering new therapeutic targets, examining disease mechanisms, and devising patient-specific therapies for numerous human diseases. Exploitation the type of genetic material isolated from patients (patient-derived cell lines, organoids, and animal models) the researchers will be able to investigate causal relationships between specific genetic changes within the studied disease, and it will give them the chance to identify potential useful targets for disease intervention (Dittami et al., 2021).

Translational Applications: Developing beyond proof-of-concept, into clinical utilization of epigenome editing technologies is on the other hand a not a straightforward task. It requires preclinical models testing, development of appropriate delivery techniques and their proof of safety and efficiency. Collaboration with the players in academia, industry, and regulatory sphere is key to trying to trace the translational steps and achieve the actual purpose of epigenetic approach to precision medicine (Bishop et al., 2019).

In sum, although challenges do exist, the breakneck tempo of innovation and collaboration in the field of epigenetics is scioting major developments in our comprehension and the planting of seeds. The scientists work towards overcoming all technical, ethical and regulatory obstacles while at the same time taking advantage of fresh innovative ideas so that they may be able to explore the full potential of epigenetic manipulation thus further advancing human health and disease treatment in the years to come.

Conclusion

Absorption of CRISPR-Cas-associated epigenome editing techniques supplementing our knowledge of gene expression as well as cellular physiology is a revolution in biomedical science and therapeutic advancement. Researchers can now specifically change the epigenetic marks by using genome methods, therefore, we are now able to understand the complicated mechanisms controlling gene expression and the cause of the anomalies in the organism that are related to the disease.

The process of both deciphering the mechanisms of developmental processes and the molecular basis of disease pathogenesis has been provided by epigenetic manipulation which has a tremendous value for the complex interaction between the epigenetic phenomena and the cellular physiology. Differential epigenetic modifications provide exciting opportunities to develop precision medicine that can resume the normal gene activity disrupted in numerous medical fields, prevent the progression of the disease and significantly improve patient prognosis.

Simultaneously, epigenetic manipulations’ true potential is conditional on the solving of technical difficulties, of providing specificity and safety, and of addressing ethical and regualtor issues. The newest findings conducted by scientists are opening the way for epigenetic engineering advances such as multiplex epigenetic editing, single-cell epigenomics, and translational medicine, among others.

As the upcoming years unfold, the endeavour of academic institutions, industry, and regulatory bodies for epigenetic technologies will play a key role in the conversion of this technology to the clinical practice and will decisively build the future of precision medicine and personalized therapeutics. In the process of unlocking epigenetics, investigators now can make the paradigm in the research and treatment of human diseases completely different, which could be the welcome in of an era of precision medicine built upon people's individual epigenetic data and treatment demands..

References

[1] Statello, L., Guo, C. J., Chen, L. L., & Huarte, M. (2021). Gene regulation by long non-coding RNAs and its biological functions. Nature reviews Molecular cell biology, 22(2), 96-118.

[2] Muhar, M., Ebert, A., Neumann, T., Umkehrer, C., Jude, J., Wieshofer, C., ... & Zuber, J. (2018). SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Science, 360(6390), 800-805.

[3] Castelán-Muñoz, N., Herrera, J., Cajero-Sánchez, W., Arrizubieta, M., Trejo, C., García-Ponce, B., ... & Garay-Arroyo, A. (2019). MADS-box genes are key components of genetic regulatory networks involved in abiotic stress and plastic developmental responses in plants. Frontiers in plant science, 10, 853.

[4] Santos-Zavaleta, A., Salgado, H., Gama-Castro, S., Sánchez-Pérez, M., Gómez-Romero, L., Ledezma-

Tejeida, D., ... & Collado-Vides, J. (2019). RegulonDB v 10.5: tackling challenges to unify classic and high throughput knowledge of gene regulation in E. coli K-12. Nucleic acids research, 47(D1), D212-D220.

[5] Koonin, E. V., & Makarova, K. S. (2019). Origins and evolution of CRISPR-Cas systems. Philosophical Transactions of the Royal Society B, 374(1772), 20180087.

[6] McGinn, J., & Marraffini, L. A. (2019). Molecular mechanisms of CRISPR–Cas spacer acquisition. Nature Reviews Microbiology, 17(1), 7-12.

[7] Shivram, H., Cress, B. F., Knott, G. J., & Doudna, J. A. (2021). Controlling and enhancing CRISPR systems. Nature chemical biology, 17(1), 10-19.

[8] Ansari, I., Chaturvedi, A., Chitkara, D., & Singh, S. (2022, August). CRISPR/Cas mediated epigenome editing for cancer therapy. In Seminars in Cancer Biology (Vol. 83, pp. 570-583). Academic Press.

[9] Mahmoud, A. M., & Ali, M. M. (2019). Methyl donor micronutrients that modify DNA methylation and cancer outcome. Nutrients, 11(3), 608.

[10] Luo, C., Hajkova, P., & Ecker, J. R. (2018). Dynamic DNA methylation: In the right place at the right time. Science, 361(6409), 1336-1340.

[11] Sankar, A., Mohammad, F., Sundaramurthy, A. K., Wang, H., Lerdrup, M., Tatar, T., & Helin, K. (2022). Histone editing elucidates the functional roles of H3K27 methylation and acetylation in mammals. Nature genetics, 54(6), 754-760.

[12] Zhang, Y., Sun, Z., Jia, J., Du, T., Zhang, N., Tang, Y., ... & Fang, D. (2021). Overview of histone modification. Histone Mutations and Cancer, 1-16.

[13] Liu, G., Yin, K., Zhang, Q., Gao, C., & Qiu, J. L. (2019). Modulating chromatin accessibility by transactivation and targeting proximal dsgRNAs enhances Cas9 editing efficiency in vivo. Genome biology, 20, 1-11.

[14] Verkuijl, S. A., & Rots, M. G. (2019). The influence of eukaryotic chromatin state on CRISPR–Cas9 editing efficiencies. Current opinion in biotechnology, 55, 68-73.

[15] Li, Xiaoyi, Wei Chen, Beth K. Martin, Diego Calderon, Choli Lee, Junhong Choi, Florence M. Chardon et al. "Chromatin context-dependent regulation and epigenetic manipulation of prime editing." Cell (2023).

[16] Feliciello, I., Pezer, Ž., Sermek, A., Bruvo Mađarić, B., Ljubić, S., & Ugarković, Đ. (2021). Satellite DNA-mediated gene expression regulation: Physiological and evolutionary implication. Satellite DNAs in Physiology and Evolution, 145-167.

[17] Li, H., Li, K., Zhang, K., Li, Y., Gu, H., Liu, H., ... & Cai, D. (2021). The Circadian physiology: implications in livestock health. International journal of molecular sciences, 22(4), 2111.

[18] Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020). Lipid nanoparticle technology for therapeutic gene regulation in the liver. Advanced drug delivery reviews, 159, 344-363.

[19] Lu, H., Sun, J., Liang, W., Zhang, J., Rom, O., Garcia-Barrio, M. T., ... & Fan, Y. (2019). Novel gene regulatory networks identified in response to nitro-conjugated linoleic acid in human endothelial cells. Physiological genomics, 51(6), 224-233.

[20] Unnikrishnan, A., Freeman, W. M., Jackson, J., Wren, J. D., Porter, H., & Richardson, A.

(2019). The role of DNA methylation in epigenetics of aging. Pharmacology & therapeutics, 195, 172-185.

[21] Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020). The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology, 17(2), 75-90.

[22] Lee, D. Y., & Chiu, J. J. (2019). Atherosclerosis and flow: roles of epigenetic modulation in vascular endothelium. Journal of Biomedical Science, 26, 1-17.

[23] Nemec, S., & Kilian, K. A. (2021). Materials control of the epigenetics underlying cell plasticity. Nature Reviews Materials, 6(1), 69-83.

[24] Poças-Fonseca, M. J., Cabral, C. G., & Manfrão-Netto, J. H. C. (2020). Epigenetic manipulation of filamentous fungi for biotechnological applications: a systematic review. Biotechnology letters, 42(6), 885-904.

[25] da Silva, R. A., Fernandes, C. J. D. C., Feltran, G. D. S., Gomes, A. M., de Camargo Andrade, A. F., Andia, D. C., ... & Zambuzzi, W. F. (2019). Laminar shear stress-provoked cytoskeletal changes are mediated by epigenetic reprogramming of TIMP1 in human primary smooth muscle cells. Journal of Cellular Physiology, 234(5), 6382-6396.

[26] Chen, D., & Kerr, C. (2019). The epigenetics of stem cell aging comes of age. Trends in cell biology, 29(7), 563-568.

[27] Hamilton, P. J., Burek, D. J., Lombroso, S. I., Neve, R. L., Robison, A. J., Nestler, E. J., & Heller, E. A. (2018). Cell-type-specific epigenetic editing at the Fosb gene controls susceptibility to social defeat stress. Neuropsychopharmacology, 43(2), 272-284.

[28] Zhang, Z., Zhai, Y., Ma, X., Zhang, S., An, X., Yu, H., & Li, Z. (2018). Down-regulation of H3K4me3 by MM-102 facilitates epigenetic reprogramming of porcine somatic cell nuclear transfer embryos. Cellular Physiology and Biochemistry, 45(4), 1529-1540.

[29] Ferrari, A., Longo, R., Silva, R., Mitro, N., Caruso, D., De Fabiani, E., & Crestani, M. (2019). Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics. Pharmacology & Therapeutics, 193, 178-193.

[30] Ji, S., Xiong, M., Chen, H., Liu, Y., Zhou, L., Hong, Y., ... & Sun, X. (2023). Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases. Signal Transduction and Targeted Therapy, 8(1), 116.

[31] Choupani, J., Mansoori Derakhshan, S., Bayat, S., Alivand, M. R., & Shekari Khaniani, M. (2018). Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial–mesenchymal transition in cancer cells. Journal of cellular physiology, 233(6), 4443-4457.

[32] Iranifar, E., Seresht, B. M., Momeni, F., Fadaei, E., Mehr, M. H., Ebrahimi, Z., ... & Mirzaei, H. (2019). Exosomes and microRNAs: new potential therapeutic candidates in Alzheimer disease therapy. Journal of cellular physiology, 234(3), 2296-2305.

[33] Fathollahi, A., Aslani, S., Jamshidi, A., & Mahmoudi, M. (2019). Epigenetics in osteoarthritis: novel spotlight. Journal of cellular physiology, 234(8), 12309-12324.

[34] Kular, L., & Kular, S. (2018). Epigenetics applied to psychiatry: clinical opportunities and future challenges. Psychiatry and clinical neurosciences, 72(4), 195-211.

[35] Han, L. K., Verhoeven, J. E., Tyrka, A. R., Penninx, B. W., Wolkowitz, O. M., Månsson, K.

N., ... & Picard, M. (2019). Accelerating research on biological aging and mental health: Current challenges and future directions. Psychoneuroendocrinology, 106, 293-311.

[36] Dittami, S. M., Arboleda, E., Auguet, J. C., Bigalke, A., Briand, E., Cárdenas, P., ... & Not, F. (2021). A community perspective on the concept of marine holobionts: current status, challenges, and future directions. PeerJ, 9, e10911.

[37] Rong, L., Li, N., & Zhang, Z. (2022). Emerging therapies for glioblastoma: current state and future directions. Journal of Experimental & Clinical Cancer Research, 41(1), 142.

[38] Bishop, D. J., Botella, J., Genders, A. J., Lee, M. J., Saner, N. J., Kuang, J., ... & Granata, C. (2019). High-intensity exercise and mitochondrial biogenesis: current controversies and future research directions. Physiology, 34(1), 56-70.